Published in J Am Soc Nephrol on October 02, 2008
Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression. Cancer Lett (2012) 2.05
Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis. Front Biosci (Landmark Ed) (2011) 1.12
CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1. J Biol Chem (2010) 1.11
Lack of CXC chemokine receptor 3 signaling leads to hypertrophic and hypercellular scarring. Am J Pathol (2010) 1.07
Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res (2009) 1.04
Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer (2012) 1.03
Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood (2010) 1.02
Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev (2012) 1.01
A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation. J Biol Chem (2013) 0.90
Role of chemokines in renal cell carcinoma. Rev Urol (2014) 0.86
CXCR3 in carcinoma progression. Histol Histopathol (2015) 0.84
Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer. Clin Exp Metastasis (2014) 0.82
Long-term High Fat Ketogenic Diet Promotes Renal Tumor Growth in a Rat Model of Tuberous Sclerosis. Sci Rep (2016) 0.78
TNF-α augments CXCR2 and CXCR3 to promote progression of renal cell carcinoma. J Cell Mol Med (2016) 0.75
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell (1991) 15.76
Chemokines: a new classification system and their role in immunity. Immunity (2000) 13.03
Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev (2003) 9.39
NFAT signaling: choreographing the social lives of cells. Cell (2002) 8.17
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med (2002) 7.06
A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med (2006) 6.86
Cancer after kidney transplantation in the United States. Am J Transplant (2004) 5.08
Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J Biol Chem (1998) 4.02
Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature (1999) 3.93
Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell (2001) 3.37
Calcineurin: a calcium- and calmodulin-binding protein of the nervous system. Proc Natl Acad Sci U S A (1979) 3.33
Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol (2008) 3.04
Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol (2002) 2.92
An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med (2003) 2.91
IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med (1993) 2.35
The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int (2007) 2.10
Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant (2004) 1.90
Chemokines in neoplastic progression. Semin Cancer Biol (2004) 1.84
CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol (2004) 1.77
Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs (2007) 1.76
Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation (2004) 1.68
CXC chemokines in angiogenesis of cancer. Semin Cancer Biol (2004) 1.65
CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res (2007) 1.61
Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res (2006) 1.58
Manganese superoxide dismutase enhances the invasive and migratory activity of tumor cells. Cancer Res (2007) 1.52
Malignancy in renal transplantation. J Am Soc Nephrol (2004) 1.50
Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res (2006) 1.43
Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene (2007) 1.42
Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation (2004) 1.40
Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant (2007) 1.37
CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immunol (2005) 1.35
Immunosuppression: practice and trends. Am J Transplant (2004) 1.28
Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum Pathol (2007) 1.22
Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation (2003) 1.16
Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J Immunol (2004) 1.12
Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res (2008) 1.11
Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation (1999) 1.08
Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant (2007) 1.08
Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B. Int J Biochem Cell Biol (2008) 1.07
The chemokine receptor CXCR3 and its splice variant are expressed in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol (2004) 1.02
The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate G alpha i-independent signaling and actin responses in human intestinal myofibroblasts. J Immunol (2005) 1.01
Expression of the interferon-inducible chemokine IP-10 (CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma. J Pathol (2005) 0.94
Cyclosporine: from renal transplantation to autoimmune diseases. Ann N Y Acad Sci (2005) 0.88
Post-transplant lymphoproliferative syndrome in the pediatric liver transplant population. Am J Transplant (2001) 0.81
The role of chemokines and chemokine receptors in progressive renal diseases. Am J Kidney Dis (2003) 0.81
In vivo luminescent imaging of cyclosporin A-mediated cancer progression in rats. Transplantation (2006) 0.81
The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opin Drug Saf (2007) 0.78
Cyclosporin-A suppresses p53-dependent repair DNA synthesis and apoptosis following ultraviolet-B irradiation. Photodermatol Photoimmunol Photomed (2002) 0.78
Identification of cells initiating human melanomas. Nature (2008) 8.28
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell (2006) 4.55
ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res (2005) 3.52
Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol (2013) 2.11
Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression. Cancer Lett (2012) 2.05
Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest (2003) 1.66
PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol (2007) 1.51
Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res (2006) 1.43
The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem (2007) 1.40
Angiogenesis and endothelial cell repair in renal disease and allograft rejection. J Am Soc Nephrol (2006) 1.25
Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gamma-inducible protein of 10 kDa in vitro and in vivo. J Immunol (2006) 1.24
Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer. PLoS One (2013) 1.13
Vascular endothelial growth factor antagonist modulates leukocyte trafficking and protects mouse livers against ischemia/reperfusion injury. Am J Pathol (2006) 1.12
Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res (2008) 1.11
CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1. J Biol Chem (2010) 1.11
Cost-related immunosuppressive medication nonadherence among kidney transplant recipients. Clin J Am Soc Nephrol (2010) 1.10
Expression patterns of vascular endothelial growth factor in human cardiac allografts: association with rejection. Transplantation (2003) 1.09
Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production. J Immunol (2009) 1.08
Heme oxygenase-1 promotes survival of renal cancer cells through modulation of apoptosis- and autophagy-regulating molecules. J Biol Chem (2012) 1.05
Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res (2009) 1.04
The heme oxygenase-1 protein is overexpressed in human renal cancer cells following activation of the Ras-Raf-ERK pathway and mediates anti-apoptotic signal. J Biol Chem (2011) 1.02
Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev (2012) 1.01
Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development. J Biol Chem (2010) 0.99
The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase. J Immunol (2004) 0.97
Subsets of human CD4(+) regulatory T cells express the peripheral homing receptor CXCR3. Eur J Immunol (2011) 0.96
Proangiogenic function of CD40 ligand-CD40 interactions. J Immunol (2003) 0.95
Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40. PLoS One (2011) 0.93
Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression. Eur J Cancer (2010) 0.93
LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's esophagus? J Exp Clin Cancer Res (2011) 0.93
Donor antigen-specific regulatory T-cell function affects outcome in kidney transplant recipients. Kidney Int (2011) 0.92
A rendezvous before rejection: where do T cells meet transplant antigens? Nat Med (2002) 0.92
Organ-specific differences in the function of MCP-1 and CXCR3 during cardiac and skin allograft rejection. Transplantation (2007) 0.92
CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. J Immunol (2008) 0.92
Every allograft needs a silver lining. J Clin Invest (2007) 0.91
Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. Pediatr Transplant (2004) 0.91
Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo. Blood (2010) 0.91
A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation. J Biol Chem (2013) 0.90
Role of insulin receptor substrates and protein kinase C-zeta in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer cells. J Biol Chem (2003) 0.90
DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses. Blood (2013) 0.89
Inhibition of the alloimmune response through the generation of regulatory T cells by a MHC class II-derived peptide. J Immunol (2008) 0.89
The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways. Cancer Lett (2013) 0.88
CD40: a mediator of pro- and anti-inflammatory signals in renal tubular epithelial cells. J Am Soc Nephrol (2005) 0.88
VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant (2013) 0.88
CD40-induced transcriptional activation of vascular endothelial growth factor involves a 68-bp region of the promoter containing a CpG island. Am J Physiol Renal Physiol (2004) 0.87
A novel in vivo regulatory role of P-glycoprotein in alloimmunity. Biochem Biophys Res Commun (2010) 0.86
Targeting the intragraft microenvironment and the development of chronic allograft rejection. Hum Immunol (2012) 0.85
Heme oxygenase-1 modulates the expression of the anti-angiogenic chemokine CXCL-10 in renal tubular epithelial cells. Am J Physiol Renal Physiol (2007) 0.84
TNP-470, an angiogenesis inhibitor, attenuates the development of allograft vasculopathy. Transplantation (2004) 0.84
Function of the vascular endothelial growth factor receptors Flt-1 and Flk-1/KDR in the alloimmune response in vivo. Transplantation (2005) 0.84
Tumour-mediated TRAIL-Receptor expression indicates effective apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer. Eur J Cancer (2010) 0.84
TRAF6 inhibits proangiogenic signals in endothelial cells and regulates the expression of vascular endothelial growth factor. Biochem Biophys Res Commun (2012) 0.82
Use of [18F]FDG Positron Emission Tomography to Monitor the Development of Cardiac Allograft Rejection. Transplantation (2015) 0.82
T-cell response to p53 tumor-associated antigen in patients with colorectal carcinoma. Int J Oncol (2006) 0.82
The role of FOXP3 in disease progression in colorectal cancer patients. Oncoimmunology (2013) 0.81
Chemokines involved in tumor promotion and dissemination in patients with renal cell cancer. Cancer Biomark (2011) 0.80
Influence of p53 on anti-tumor immunity (review). Int J Oncol (2006) 0.79
Antiproliferative effects of fluoxetine on colon cancer cells and in a colonic carcinogen mouse model. PLoS One (2012) 0.79
Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermia. Ann Surg Oncol (2013) 0.79
Selectin blockade plus therapy with low-dose sirolimus and cyclosporin a prevent brain death-induced renal allograft dysfunction. Am J Transplant (2005) 0.78
Long-term care of pediatric renal transplant patients: from bench to bedside. Curr Opin Pediatr (2002) 0.78
Segment 4 and the left lateral segment regeneration pattern after resection of the middle hepatic vein in a living donor right hepatectomy. HPB (Oxford) (2014) 0.78
Glucagon-like peptide 2 in colon carcinogenesis: possible target for anti-cancer therapy? Pharmacol Ther (2013) 0.77
Prolongation of small bowel allograft survival with a sequential therapy consisting of a synthetic MHC class II peptide and temporarily low-dose cyclosporine A. Hum Immunol (2002) 0.77
Differential activation of human T cells to allogeneic endothelial cells, epithelial cells and fibroblasts in vitro. Transplant Res (2012) 0.77
Association of steroid use with complicated sigmoid diverticulitis: potential role of activated CD68+/CD163+ macrophages. Langenbecks Arch Surg (2011) 0.77
Fever-range temperature modulates activation and function of human dendritic cells stimulated with the pathogenic mould Aspergillus fumigatus. Med Mycol (2014) 0.77
Chronic rejection: insights from a novel immunosuppressive-free model of kidney transplantation. J Am Soc Nephrol (2004) 0.77
Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer. Ann Surg Oncol (2007) 0.77
Chronic allograft rejection: a fresh look. Curr Opin Organ Transplant (2015) 0.77
Colon preneoplasia after carcinogen exposure is enhanced and colonic serotonergic system is suppressed by food deprivation. Toxicology (2013) 0.77
Pre-transplant angiotensin II type 1 receptor antibodies: A risk factor for decreased kidney graft function in the early post-transplant period? Clin Transpl (2013) 0.77
Pre-transplant angiotensin II type 1receptor antibodies: a risk factor for decreased kidney graft function in the early post-transplant period? Rev Invest Clin (2015) 0.76